Evidence map›Paper›PMID 28253927›Full record

ArticleRespiratory research2017

Low tissue levels of miR-125b predict malignancy in solitary fibrous tumors of the pleura.

Matthias Brock, Selma Hottinger, Matthias Diebold, Alex Soltermann, Wolfram Jochum, Malcolm Kohler, Lars C Huber, Daniel P Franzen

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Respiratory research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Matthias BrockDepartment of Pulmonology, University Hospital Zurich, University of Zurich, Rämistr. 100, 8091, Zurich, Switzerland.
Selma HottingerDepartment of Pulmonology, University Hospital Zurich, University of Zurich, Rämistr. 100, 8091, Zurich, Switzerland.
Matthias DieboldDepartment of Pulmonology, University Hospital Zurich, University of Zurich, Rämistr. 100, 8091, Zurich, Switzerland.
Alex SoltermannDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Wolfram JochumInstitute of Pathology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Malcolm KohlerDepartment of Pulmonology, University Hospital Zurich, University of Zurich, Rämistr. 100, 8091, Zurich, Switzerland.
Lars C HuberDepartment of Pulmonology, University Hospital Zurich, University of Zurich, Rämistr. 100, 8091, Zurich, Switzerland.
Daniel P FranzenDepartment of Pulmonology, University Hospital Zurich, University of Zurich, Rämistr. 100, 8091, Zurich, Switzerland. daniel.franzen@usz.ch.
University Hospital of Zurich · CHUniversity of St. Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSolitary fibrous tumors of the pleura (SFTP) are rare neoplasia of the chest. A subset of SFTP follows a malignant course, sometimes several years after complete resection. Traditional scoring systems based on clinical and histological features are poor predictors of biological behavior. This study aimed to investigate tumor-associated miRNAs expression as novel biomarkers to predict the clinical behavior of SFTP.

methodsFormalin-fixed and paraffin-embedded SFTP tissues blocks from patients surgically resected between 1992 and 2013 at two tertiary care teaching hospitals were included. SFTP tumors were categorized as either malignant or benign variants according to the WHO classification. Following miRNAs levels were measured: let-7a, miR-16b, miR-17, miR-21, miR-31, miR-34a, miR-92a, miR-125a, miR-125b, miR-195-5b, miR-203a, and miR-223. Differential gene expressions which were calculated with the threshold cycle (C

resultsThirty-eight patients (40% male, mean age 62.2 (±10.9) years) were included. Expression levels of miR-125b showed a significant difference between benign compared to malignant variants (-3.08 ± 0.93 vs. -2.22 ± 1.36, p = 0.0068). Furthermore, lower levels of miR-125b were found to be associated with increased tumor size (p = 0.0414). Thus, downregulation of miR-125b indicates malignant transformation. All other investigated miRNAs were not associated with grading of SFTP.

conclusionsOur data suggest a potential role of miR-125b in the pathogenesis of tumor growth and malignant transformation of SFTP, respectively. Further studies have to address the potential use of miRNA-125b as a biomarker or therapeutic target in SFTP.

Indexed as

Biomarkers, TumorFemaleHumansMaleMicroRNAsMiddle AgedPrognosisReproducibility of ResultsSensitivity and SpecificitySolitary Fibrous Tumor, PleuralSwitzerlandBiomarkers, TumorMicroRNAsMIRN125 microRNA, humanBiomarkermicroRNAPleuraSolitary fibrous tumor

Identifiers

PMID28253927
PMCPMC5335791
OpenAlexW2594852999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.